The company said revenue for Q2 2025 rose to $1,109 million, up 11% as reported and 9% organically. Diluted EPS for Q2 was $3.63, up 49% as reported and 17% on a comparable basis.

1. 01

   The company said revenue for Q2 2025 rose to $1,109 million, up 11% as reported and 9% organically. Diluted EPS for Q2 was $3.63, up 49% as reported and 17% on a comparable basis.

2. 02

   IDEXX said its operating margin for Q2 was 33.6%, up 730 basis points from the prior-year period as reported and 130 basis points on a comparable basis. The company said the comparison to the prior-year discrete litigation expense accrual of $61.5 million accounted for about 600 basis points.

3. 03

   The company said CAG Diagnostics recurring revenue for Q2 grew 8.6% as reported and 7.4% organically. CAG Diagnostics capital instrument revenue rose 66.0% as reported and 62.5% organically.

4. 04

   The company said it raised its 2025 full-year revenue outlook to $4,205 million to $4,280 million, from $4,095 million to $4,210 million previously, an increase of $90 million at the midpoint. It set its full-year EPS outlook at $12.40 to $12.76, compared with a prior outlook of $11.93 to $12.43.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.